Merck to Release Findings from Integrated Analysis of Six Phase 2 and 3 Clinical Trials Evaluating Investigational Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1, 4 or 6 Infection and Compensated Cirrhosis at The Liver Meeting

Merck

, known as MSD outside the United States and Canada, today announced the presentation of results from an integrated analysis of patients with compensated liver cirrhosis (Child-Pugh class A) from six Phase 2 and 3 clinical trials evaluating the efficacy and safety of the investigational once-daily tablet elbasvir/grazoprevir1 (50mg/100mg) with or without ribavirin (RBV) in patients with chronic hepatitis C virus (HCV) genotypes (GT) 1, 4 or 6 infection. Results from the full analysis set (FAS) (n=402) demonstrate that treatment-naïve patients with compensated liver cirrhosis who received elbasvir/grazoprevir with or without RBV for 12 weeks achieved sustained virologic response 12 weeks after the completion of treatment (SVR12, or virologic cure) at rates of 90 percent (28/31) and 98 percent (135/138),